Advertisement
Australia markets closed
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • AUD/USD

    0.6615
    -0.0022 (-0.34%)
     
  • OIL

    78.55
    -0.07 (-0.09%)
     
  • GOLD

    2,348.80
    +30.80 (+1.33%)
     
  • Bitcoin AUD

    98,832.97
    -1,988.23 (-1.97%)
     
  • CMC Crypto 200

    1,379.17
    -38.70 (-2.73%)
     
  • AUD/EUR

    0.6177
    +0.0005 (+0.08%)
     
  • AUD/NZD

    1.0770
    +0.0018 (+0.17%)
     
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NASDAQ

    19,646.43
    +69.51 (+0.36%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,553.61
    -93.49 (-0.24%)
     
  • DAX

    18,002.02
    -263.66 (-1.44%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

Inspire Medical Systems, Inc. to Present at the Jefferies Global Healthcare Conference

Inspire Medical Systems
Inspire Medical Systems

MINNEAPOLIS, May 23, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024.

Inspire is scheduled to present at 11:30 a.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

ADVERTISEMENT

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443